Electrochemotherapy with intra-tumoral cisplatin for the treatment of fibrosarcoma in a horse

DOI: 10.18805/ijar.B-3532    | Article Id: B-3532 | Page : 541-544
Citation :- Electrochemotherapy with intra-tumoral cisplatin for the treatment of fibrosarcoma in a horse.Indian Journal Of Animal Research.2019.(53):541-544
M. Bharathidasan, B. Justin William, Ravi Sundar George, A. Arunprasad and R. Sivasankar dasan.bharathi234@gmail.com
Address : Department of Veterinary Surgery and Radiology, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai-600 051, Tamil Nadu, India.
Submitted Date : 29-11-2017
Accepted Date : 15-01-2018


A two years old Kathiawar stallion was reported with the history of two, pedunculated hard mass medially on the thigh and hock of the right hind limb, progressively increasing for the past two months. Fine needle aspiration cytology revealed fibrosarcoma.The tumour on the medial aspect of the thigh was injected with cisplatin intra-tumorally at a dose rate of 0.3 mg/cm3 of tumour volume and was exposed to ECT. The tumour on the medial aspect of the hock was excised incompletely to preserve skin and subcutaneous tissues around the tumour for wound opposition and treated with intra-tumoral injection of cisplatin followed by ECT. Following  electrochemotherapy complete response was noticed onthe 3rd and 4th week for the tumours on the thigh and hock respectively. No recurrence was noticed during the follow-up period of one year revealing ETC with cisplatin as a single treatment and also in combination with surgery is effective for the treatment of fibrosarcoma in equines. 


Cisplatin Electrochemotherapy Equines Fibrosarcoma.


  1. Bass, K., Mochal-King, C.A.,Cooley A. J.,and Brinkman,E. ( 2017) Case Report Equine Mandibular Fibrosarcoma in Two Horses: Clinical, Diagnostic and Therapeutic Considerations. J. Equine Vet Sci.,48: 31–33.
  2. Basu, A. and Krishnamurthy, S. (2010) Review Article Cellular Responses to Cisplatin-Induced DNA Damage. J Nucleic Acids, vol. 2010, Article ID 201367, 16 pages, 2010. doi:10.4061/2010/201367.
  3. Campana, L.G., Marconato, R.,Sieni, E.,Valpione, S.,Corti, L.,Mocellin S. and Rossi,C.R. (2016) Electrochemotherapy: mechanism of action and clinical results in the locoregional treatment of patients with skin cancers and superficial metastases. Recenti Progressi in Medicina, 107:422-43.
  4. Cemazar, M., .Avgustin, A.J.,Pavlin, D., Sersa, G.,Poli, A.,Levacic, K.A., Tesic, N., et al., (2017) Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours. Vet Comp Oncol. 15(2):641-654.
  5. Hang, Z., Cooper M. A.,and Ziora, Z. M.,92016) Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials. Biochemical Compounds, 4:1-10.
  6. Kodre, V.,Cemazar, M.,Pecar, J.,Sersa,G.,Cor A. and Tozon, N. (2009) Electrochemotherapy Compared to Surgery for Treatment of Canine Mast Cell Tumours. in vivo, 23: 55-62.
  7. Ma, P., Xiao, H.,Li, C.,Dai, Y.,Cheng, Z.,Hou Z. and Lin, J. (2015) Inorganic nanocarriers for platinum drug delivery. Materials Today, 18(10):554-564.
  8. Mir, J., Gehld, M.L., Sersae, G.,Collins, C. G., Garbaya, J.R., Billarda , V., et al., (2006) Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. European J. Cancer, Supplements, 4:14-25.
  9. Mitroviæ,A., Sosic, I., Kos, S.,Tratar, U. L.,Breznik, B.,Kranjc, S.,Mirkovic, B., et al., (2017) Addition of 2-(ethylamino) acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo. Oncotarget,8 (35): 59136-59147.
  10. Nejdl, L., Kudr, J., Blazkova, I., Chudobova, D., Skalickova, S., Ruttkay-Nedecky, B., Adam, V.and R. Kizek, 2014. Mechanisms of Uptake and Interaction of Platinum Based Drugs in Eukaryotic Cells. Metallomics, 6(11):2126-2133.
  11. Rabik, C.A. and Dolan, M. E. (2007) Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents. Cancer Treat Rev. 33(1): 9-23.
  12. Sengela, T.J., and Wallacea,M.(2016) Imaging the dynamics of individual electropores. Proc. Natl. Acad. Sci U S A. 113(19): 5281-5286.
  13. Sersa, G., Stabuc, B.,Cemazar, M.,Miklavcic D. and Rudolf, Z. (2000) Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res., 10: 381±385
  14. Spugnini, E.P., Vincenzi, B.,Baldi, F.,Citro G. and Baldi, A. (2006)Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors.Anticancer Res. 26(6B):4585-4589.
  15. Sugita, Y., Miyamoto, Y.,Anuudari, E.,Torii, R., Kato, S.,Kawai1 R. and Yoshida, W., et al., (2012) Potentiation of the Anti-tumour Effect of Cisplatin by Administering Local Electrical Pulses to Metastatic Lesions of Hamster Oral Fibrosarcoma. J. Hard Tissue Biology21(4): 451-458.
  16. Taylor, E.V., Baetge,C.L., Matthews,N.S.,Taylor,T.S.andK.S.(2008) Guaifenesin-Ketamine-Xylazine Infusions to Provide Anesthesia in Donkeys. J Equine Vet Sci. 28(5): 295-300.
  17. Zhao, X., Zhang, M. and Yang, R.2010. Control of pore radius regulation for electroporation-based drug delivery.Commun Nonlinear Sci Numer Simul.15(5): 1400-1407. 

Global Footprints